

Version : 2 Applicable le : 14-07-2023

RB-9-DE-005



Document to be filled by the applicant.

To be sent to the BRC contact person or to CRB@chu-montpellier.fr.

This request will be forwarded to the BRC's Scientific Council for approval.

Each element of this request will be handled by the CHU in a strictly confidential manner.

Request Date (JJ/MM/AAAA):

FRAME RESERVE	D IO CRB							
Date of receipt of the request:								
CRB thematic manager:								
CRB - CHU de Montpellier								
Thematic / collection:								
Address:								
Phone number:	ber: E-mail: @							
If collection, please	e complete:							
Name of	Responsible	Phone number	E-mail	DC Number	AC Number			
collection	(name and							
	surname)							
_								
APPLICANT								
Full name, Position	1:							
Institution/laboratory:								
Address:	o. y.							
Phone number:		Fax:						
E-mail: @	D .							
	•							
A DDLLC A NIT'S INS	TITUTIONAL (ADI	MINISTRATION) C	ONTACT					
	<u> </u>	VIINISTRATION) C	UNTACT					
Full name, Position	1:							
Institution/laborate	ory:							
Address:								
Phone number:		Fax:						
E-mail:	@							



RB-9-DE-005 Version : 2 Applicable le : 14-07-2023



RESEARCH PROJECT (join Project de	scription - Synopsis)							
Acronym + Project title:								
tarting date: Ending date:								
Project coordinator:	Project coordinator:							
Address:								
Phone: Fax:								
Mail: @								
Partnership / Research Collaboration with CHU:☐ Yes (Please fill below) ☐ No								
Co-authorship in future publica	tions: 🗖 Yes	□ No						
Intellectual Property sharing:	☐ Yes	□ No						
Other partnership elements:								
PROJECT DETAILS:								
Date of the desired provision (JJ/MM/A	AAA):							
Pathology:								
Inclusion / Exclusion criteria:								
Number of patients: Age of patients: ☐ Female ☐ Male								
This project includes:								
External analyses (other labora	tories, subcontractors)? 🗖 Yes 💢 🗖 I	No						
If "Yes" please specify de type of ar	nalyses, name and address of the com	pany:						
2) Genetic analyses on the materi	·							
If "Yes" what type of genetic analyses are included? * Constitutive (i.e. analyses of the genetic characteristics of a person that were inherited or								
acquired at an early stage of prenatal development):								
acquired at air early stage of prenatal developments.								
•	analyses of the genetic characteristic							
character is of unknown firs	t intention):	ibe below) 🗖 No						
3) Material transfer outside from	France?							
If "Yes" an export application to the French Research Ministry is required; the period to obtain the								
authorization is of at least 3 month	s.							
Requested biological material descri	ription for the research :							
TISSUES AND TUMORS								
		Characteristics						
C Silano coated slides	volume, weight, etc.)							
☐ Silane coated slides								
☐ HE slides								



RB-9-DE-005 Version : 2 Applicable le : 14-07-2023



☐ Immuno slides					
☐ TMA slides					
☐ Coloured slides					
☐ Paraffin block					
☐ Block in TMA					
☐ Immunohistochemistry (specify)					
☐ Tissue array punches in buffer					
☐ Tissue fragments, frozen					
☐ Tissue fragments, fresh					
☐ Frozen sections (number, buffer):				frozen or 🗖 fresh	
Derived products: ☐ DNA or ☐ RNA				frozen or \square fresh	
☐ Skin sampling					
☐ Amniotic membrane					
☐ Cornea					
☐ Blood placental					
☐ Skeletal muscle					
☐ Other					
BIOLOGICAL FLUIDS					
Nature of samples		Quantity by patient		Characteristics	
	1	u valuma vuaimbe atal			
	(numbe	r, volume, weight, etc)			
☐ Plasma	(numbe	r, volume, weight, etc)	☐ EDTA	☐ heparinized ☐ fluorinated	
☐ Serum	(numbe	r, volume, weight, etc)	☐ EDTA	☐ heparinized ☐ fluorinated	
☐ Serum ☐ Total blood	(numbe	r, volume, weight, etc)	□ EDTA	☐ heparinized ☐ fluorinated	
☐ Serum ☐ Total blood ☐ Urine	(numbe	r, volume, weight, etc)	☐ EDTA	☐ heparinized ☐ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF	(numbe	r, volume, weight, etc)	☐ EDTA	☐ heparinized ☐ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC	(numbe	r, volume, weight, etc)	☐ EDTA	☐ heparinized ☐ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva	(numbe	r, volume, weight, etc)	☐ EDTA	□ heparinized □ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool	(numbe	r, volume, weight, etc)	☐ EDTA	□ heparinized □ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool Derived products:☐ DNA or ☐ RNA	(numbe	r, volume, weight, etc)	□ EDTA	□ heparinized □ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool Derived products:☐ DNA or ☐ RNA ☐ Other	(numbe	r, volume, weight, etc)	□ EDTA	□ heparinized □ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool Derived products:☐ DNA or ☐ RNA	(numbe	r, volume, weight, etc)	□ EDTA	□ heparinized □ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool Derived products:☐ DNA or ☐ RNA ☐ Other Details / Comments:	(numbe	r, volume, weight, etc)	□ EDTA	□ heparinized □ fluorinated	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool ☐ Derived products:☐ DNA or ☐ RNA ☐ Other ☐ Details / Comments:	(numbe				
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool Derived products:☐ DNA or ☐ RNA ☐ Other Details / Comments:	(numbe	Quantity by patient	(number,	☐ heparinized ☐ fluorinated Characteristics	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool ☐ Derived products:☐ DNA or ☐ RNA ☐ Other ☐ Details / Comments: CELLS Nature of samples	(numbe		(number,	Characteristics	
☐ Serum ☐ Total blood ☐ Urine ☐ LCSF ☐ PBMC ☐ Saliva ☐ Stool ☐ Derived products:☐ DNA or ☐ RNA ☐ Other ☐ Details / Comments: CELLS Nature of samples ☐ Cells		Quantity by patient	(number,		
□ Serum □ Total blood □ Urine □ LCSF □ PBMC □ Saliva □ Stool Derived products:□ DNA or □ RNA □ Other Details / Comments: CELLS Nature of samples □ Cells □ Bone Marrow of patients with multiple of the samples of th		Quantity by patient	(number,	Characteristics	
□ Serum □ Total blood □ Urine □ LCSF □ PBMC □ Saliva □ Stool Derived products:□ DNA or □ RNA □ Other Details / Comments: CELLS Nature of samples □ Cells □ Bone Marrow of patients with multimyeloma	tiple	Quantity by patient	(number,	Characteristics	
□ Serum □ Total blood □ Urine □ LCSF □ PBMC □ Saliva □ Stool □ Derived products:□ DNA or □ RNA □ Other □ Details / Comments: CELLS Nature of samples □ Cells □ Bone Marrow of patients with multimyeloma □ Non-tumoral cells of bonne marrow	tiple	Quantity by patient	(number,	Characteristics	
□ Serum □ Total blood □ Urine □ LCSF □ PBMC □ Saliva □ Stool Derived products:□ DNA or □ RNA □ Other Details / Comments: CELLS Nature of samples □ Cells □ Bone Marrow of patients with multimyeloma	tiple	Quantity by patient	(number,	Characteristics	



RB-9-DE-005 Version : 2 Applicable le : 14-07-2023



Details / Comments:
ASSOCIATED DATAS
☐ None ☐ Minimum « Data Set » (age, sex, pathology) ☐ Anapath anonimized report
☐ Other:
MATERIAL TRANSPORTATION
Transportation:
Conditions of transport: ☐ Room Temperature ☐ Dry ice ☐ Ice
Details: Safety rules to apply for infectious agents
Location and conditions of storage and use:
Delivery: Hand delivered Carrier
FATE AT THE END OF THE PROJECT ☐ Full use of the material ☐ Return to BRC ☐ Destruction (with a full declaration sent to the BRC)
FINANCING MODALITIES (a quote will be sent to you with the contract)
Is there a budget for this request? ☐ Yes ☐ No
Planned amount:
Customer Information:
Name:
Address of hill if different:
 Address of bill if different: SIRET number:
TVA number:
Contact name:
Electronic bill (Chorus Pro) :

APPLICANT COMMITMENT FOR EVERY PROGRAM

When signing this document, the applicant commits:

- To respect the legislation in force for the use of biological samples for scientific research in France and (Applicant country);
- To use the samples here above specified only for the scientific research described in my request;



Version : 2 Applicable le : 14-07-2023

RB-9-DE-005



- To give up on no account, for the benefit of a third party, samples for researches different from those which are described in my request;
- Not to use the obtained samples or their biological by-products in a for-profit purpose, this provision does not concern the use of data (results) obtained from the samples or their by-products;
- To inform the person in charge of the collection of the end of the research project;
- To recognize the scientific and/or technical contribution of the Biological Resources Center (BRC) of the University Hospital of Montpellier (CHUM) in any publication showing results obtained through the use of the given samples: either by proposing co-authorship to the persons from the collection directly involved in the research and development collaboration, according to their degree of implication.

or by quoting the scientific and/or technical contribution of the BRC CHUM collection in the "Materials and methods" section in the following way: "This works benefited from the facilities and the expertise of the BRC CHUM of the University Hospital of Montpellier (www.chu-montpellier.fr) and it's collection (<a href="Materials and the expertise of the BRC CHUM of the University Hospital of Montpellier (www.chu-montpellier.fr) and it's collection (<a href="Waterials and the expertise of the BRC CHUM of the University Hospital of Montpellier (www.chu-montpellier.fr) and it's collection (<a href="Waterials and the expertise of the BRC CHUM of the University Hospital of Montpellier (www.chu-montpellier.fr) and it's collection (Name de collection)."

CHU Montpellier, Centre de Ressources Biologiques du CHU de Montpellier, (CRB-CHUM), Collection Name de collection, F-34285 Montpellier, France

- To inform the BRC of the quality of the samples received and the associated data using the Satisfaction Survey that will be provided after the transfer;
- To destroy the remaining material at the end of research, with a statement of destruction sent to the person in charge of the collection.

APPLICANT DATA MANAGEMENT

By filling this document and any other CRB document, the applicant consents the CRB to use its personal data. The applicant authorizes the CHU to trace and keep, within the limit of the duration of the contracts, all the data known as "partner" (name, first name, company, postal and telephone details, emails, etc.) in its database/software as well as all documents used by the CRB for the management of the requests and contracts.

The data collected are for internal use only. They will neither be communicated nor transferred to third parties. The applicant can exercise its right to correction or opposition by contacting the CRB by e-mail: crb-dri@chu-montpellier.fr.

(Made in duplicate originals)

The Applicant	The Collection manager
Full name:	Full name:
Position:	Position:
Date:	Date:
Signature:	Signature:

If necessary, thank you for duplicating the signature pad so that all stakeholders on the part of the applicant are signatories



RB-9-DE-005 Version : 2 Applicable le : 14-07-2023



Associated data (reserved to CRB)
Request of associated data from the data warehouse e-Match
. □ Yes □ No
If yes, fill in the dictionary of variables
Context of the request:
Deadline :
Cost redistribution of EB and associate data (reserved to CRB)
Thank you to the CRB team partner of this contract for attaching to this document the RB-9-DE-003 form for the
redistribution of the costs of biological resources.
Notice and recommendations of the CRB Scientific Council (Reserved to CRB)
□ Acceptance □ Refusal
☐ Further information request:
President of the CRB Scientific Council or his representative
Name:
Date:
Signature: